Fascin‐1 as a novel diagnostic marker of triple‐negative breast cancer

Abstract

In some cases of breast cancer, diagnosis of triple‐negative breast cancer (TNBC) requires further fluorescence in situ hybridization (FISH) for determining human epidermal growth factor receptor 2 (HER2) status. However, few cases undergo FISH in China, leading to difficulty regarding subsequent treatment decisions. Here, we used immunohistochemical analysis to explore expression of fascin‐1, an actin‐bundling protein, as a diagnostic marker of TNBC. A total of 457 cases of breast cancer were divided into four molecular subtypes, including 82 cases (17.9%) of TNBC, 81 (17.7%) of HER2‐enriched, 185 (40.5%) of luminal A, and 109 (23.9%) of luminal B. Positive fascin‐1 expression was seen in 144 cases (31.5%), including 77 (16.8%) strong positive cases. Rates of positive and strong positive expression of fascin‐1 were significantly higher in cases of TNBC than in the other molecular subtypes. In all cases of breast cancer, the sensitivities and specificities of positive and strong positive fascin‐1 expression for predicting TNBC were 87.8% and 80.8%, and 78.0% and 96.5%, respectively. In cases of hormone receptor–negative breast cancer, the sensitivities and specificities of positive and strong positive fascin‐1 expression for predicting TNBC were 87.8% and 61.7%, and 78.0% and 92.6%, respectively. In 24 cases with estrogen receptor (ER)‐, PR‐, and HER2 2 + equivocal status who underwent FISH, the sensitivity and specificity of strong positive fascin‐1 expression for predicting TNBC were 71.4% and 90.0%. These results suggest that strong positive fascin‐1 expression can be used as a diagnostic marker of TNBC.

New role of the antidepressant imipramine as a Fascin1 inhibitor in colorectal cancer cells

“…The high frequency of KRAS or BRAF mutations confers SAC with an important resistance to current anti-epidermal growth factor receptor therapies 9,10 . Similarly, several authors have reported that fascin1 is overexpressed in triple negative/basal phenotype breast carcinoma [22][23][24] . Given the role of fascin1 in invasion and metastasis, we performed a bioinformatic search for in silico identification of chemical compounds blocking this protein.…”

Impacts of RETN genetic polymorphism on breast cancer development

“…We also enrolled 154 untreated women scheduled for breast cancer surgery at the Affiliated Dongyang Hospital of Wenzhou Medical University (Dongyang, Zhejiang, China) between 2007 and 2017; one tissue specimen was obtained from each participant. Tumor grades were assigned using the Scarff-Bloom-Richardson system and the World Health Organization breast tumor classification criteria were used for pathohistological diagnosis [23] Cases were assigned estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 status and subtyped as Luminal A (ER-positive [+] and/or PR + , HER2-negative [-], Ki-67 <14%), Luminal B (ER + and/or PR + , HER2 -, Ki-67 ≥14%, ER + and/or PR + , HER2 + ), HER2-enriched (ER -, PR -, HER2 + ), or as triple-negative breast cancer (TNBC; ER -, PR -, HER2 -) [24,25,26]. Clinicopathological information was collected from electronic medical records and at study entry each study participant completed a standardized questionnaire providing sociodemographic data.…”

Clinical significance of fascin-1 and laminin-5 in non-small cell lung cancer

“…Previous studies have showed that both the expression of fascin-1 and laminin-5 were associated with the invasiveness and prognoses of several cancers, including colorectal (Adams, 2015;Fukazawa et al, 2015), gastric (Saito et al, 2010;Tu et al, 2016), pancreatic (Tsai et al, 2013;Chen et al, 2015) cancers and breast adenocarcinomas (D'Alfonso et al, 2015;Wang et al, 2016). Recently, some authors reported that the expression of fascin-1 and laminin-5 were associated with clinico-pathological characteristics of non-small cell lung cancer (Moriya et al, 2001;Niki et al, 2002;Pelosi et al, 2003;Choi et al, 2006;An et al, 2012;Ling et al, 2015;Luo et al, 2015;Zhao et al, 2015;Liu et al, 2016).…”